Pharmaceutical executives took a verbal beating, but didn't concede much in a high-profile testimony before the Senate Finance Committee.
Even though hospitals' Medicare margins continued to decline in 2017, their total all-payer margins climbed to a near-high level, preliminary data from the Medicare Payment Advisory Commission shows.
The Affordable Care Act helped Democrats regain control of the House in 2018. But is the status quo enough to stave off progressives' demand for movement to a single-payer program?
Industry stakeholders told the CMS that they oppose banning accrediting organizations like the Joint Commission from providing consulting services.
Healthcare spending growth will rise at an annual average of 5.5% over the next decade, slightly faster than in the past few years, due to the aging of the baby boomers and healthcare price growth, the CMS reported Wednesday.
The proposal marks another major milestone for the advanced cancer treatment and could be a windfall for hospitals.
Democrats in Congress have revived the first of a slate of ideas to expand public coverage with a Medicare buy-in at age 50 bill as industry closes ranks in opposition.
While Republican lawmakers insist trimming Medicare and Medicaid is the only way to rein in federal spending, researchers have found the programs have done a better job at controlling spending than private payers.
The proposal led by Rep. Lloyd Doggett (D-Texas) and Sen. Sherrod Brown (D-Ohio) would let the government override patents if manufacturers don't play ball on drug prices for Part D.
Commercial and Medicare Advantage plans pay mental health providers in their networks significantly lower rates than traditional Medicare pays, which likely reduces access for patients.
About one-third of Medicare ACOs have until Feb. 19 to decide if they want to renew their Medicare Shared Savings Program contract in light of changes made to the program. The ACOs say that's not a lot of time to figure out if they should assume more risk.
After HHS proposed eliminating the safe harbor protection for Medicare Part D drug rebates, Secretary Alex Azar suggested commercial plans will also get rid of the rebates in order to align with the market.